X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA WOCKHARDT LTD. ELDER PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x -0.2 -18.8 - View Chart
P/BV x 0.1 3.1 3.3% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ELDER PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
WOCKHARDT LTD.
Mar-17
ELDER PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3801,129 33.7%   
Low Rs188627 30.0%   
Sales per share (Unadj.) Rs491.2363.1 135.3%  
Earnings per share (Unadj.) Rs-3.2-20.4 15.6%  
Cash flow per share (Unadj.) Rs14.4-7.0 -206.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs376.5301.8 124.7%  
Shares outstanding (eoy) m20.54110.55 18.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.62.4 23.9%   
Avg P/E ratio x-89.3-42.9 207.9%  
P/CF ratio (eoy) x19.7-125.9 -15.7%  
Price / Book Value ratio x0.82.9 25.9%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m5,83397,063 6.0%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1799,665 22.5%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m10,08940,146 25.1%  
Other income Rs m2571,143 22.5%   
Total revenues Rs m10,34641,289 25.1%   
Gross profit Rs m-792128 -618.7%  
Depreciation Rs m3611,489 24.3%   
Interest Rs m2,7562,253 122.4%   
Profit before tax Rs m-3,653-2,472 147.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-211 -59.3%   
Profit after tax Rs m-65-2,260 2.9%  
Gross profit margin %-7.80.3 -2,461.8%  
Effective tax rate %-3.48.5 -40.1%   
Net profit margin %-0.6-5.6 11.5%  
BALANCE SHEET DATA
Current assets Rs m9,24046,160 20.0%   
Current liabilities Rs m9,99819,258 51.9%   
Net working cap to sales %-7.567.0 -11.2%  
Current ratio x0.92.4 38.6%  
Inventory Days Days46101 46.0%  
Debtors Days Days6094 63.7%  
Net fixed assets Rs m10,12440,165 25.2%   
Share capital Rs m206553 37.2%   
"Free" reserves Rs m5,58232,814 17.0%   
Net worth Rs m7,73433,367 23.2%   
Long term debt Rs m4,88931,903 15.3%   
Total assets Rs m22,88289,687 25.5%  
Interest coverage x-0.3-0.1 334.9%   
Debt to equity ratio x0.61.0 66.1%  
Sales to assets ratio x0.40.4 98.5%   
Return on assets %11.80 -136,977.7%  
Return on equity %-0.8-6.8 12.5%  
Return on capital %22.3-0.3 -6,655.3%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3079,121 3.4%   
Fx outflow Rs m1252,133 5.9%   
Net fx Rs m1816,988 2.6%   
CASH FLOW
From Operations Rs m11,754-2,695 -436.2%  
From Investments Rs m-561-6,863 8.2%  
From Financial Activity Rs m-6,76212,545 -53.9%  
Net Cashflow Rs m4,4323,010 147.2%  

Share Holding

Indian Promoters % 39.6 74.5 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 2.3 326.1%  
FIIs % 16.8 7.7 218.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 36.1 15.4 234.4%  
Shareholders   16,479 67,757 24.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - NOVARTIS COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS